Physician profile
Steven Broderick
NPI 1164877882
$3,058.11
in general payments reported to CMS, 2019-2025
30 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.08 · 2021: $147 · 2022: $164 · 2023: $688 · 2024: $918 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.86 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $483.81 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $437.20 | 2023-2025 | Vraylar, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $360.18 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $194.44 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $180.52 | 2024-2025 | |
| Corium, LLC | $163.69 | 2022-2025 | Azstarys |
| Viiv Healthcare Company | $111.66 | 2024-2025 | Apretude |
| Neos Therapeutics, LP | $103.76 | 2022-2023 | Adzenys Xr-Odt |
| Gilead Sciences, INC. | $102.33 | 2025 | |
| Exact Sciences Corporation | $92.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ironshore Pharmaceuticals INC. | $89.28 | 2022-2024 | |
| Lilly USA, LLC | $89.24 | 2021-2024 | Zepbound, Mounjaro |
| Tris Pharma INC | $76.79 | 2023-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $52.40 | 2023 | Bexsero, Pediarix |
| Idorsia Pharmaceuticals US INC | $52.06 | 2023-2024 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.47 | 2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $44.40 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $43.78 | 2023 | Aptima |
| Collegium Pharmaceutical, INC. | $42.59 | 2025 | Jornay Pm |
| Amgen INC. | $41.25 | 2024-2025 | Otezla, Krystexxa |
| Csl Behring | $39.02 | 2025 | Andembry |
| Noven Therapeutics, LLC | $38.49 | 2025 | Xelstrym |
| Dexcom, INC. | $32.27 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $29.19 | 2022 | |
| Abbott Laboratories | $20.37 | 2025 | Freestyle Libre 3 |
| Seqirus USA INC | $19.17 | 2025 | Flucelvax, Fluad |
| Orexo US, INC. | $19.10 | 2024 | Zubsolv |
| Takeda Pharmaceuticals U.S.A., INC. | $18.23 | 2023 | Trintellix |
| Mayne Pharma Commercial LLC | $16.73 | 2023 | |
| Esperion Therapeutics, INC. | $16.59 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Broderick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.